Themis Medicare Q4 FY26: Revenue Up 6.7% to ₹76.5 Cr, PAT Turns Positive
Themis Medicare reported Q4 FY26 consolidated revenue of ₹76.5 crore, up 6.7% YoY. PAT turned positive at ₹8.9 crore from a loss of ₹9.7 crore. For FY26, revenue was ₹342.2 crore. The company is focusing on operational efficiencies and cost optimization to drive future growth.
The positive financial turnaround in the quarter and optimistic outlook suggest a positive impact on investor sentiment and potential future performance, though the full-year revenue decline needs to be monitored.
The company has shown a significant turnaround in profitability for Q4 FY26, with revenue growth and PAT turning positive after a loss in the previous year. Management commentary is optimistic about future performance.
Themis Medicare Limited has announced its financial results for the fourth quarter and full fiscal year 2026. For Q4 FY26, the company reported a consolidated revenue of ₹76.5 crore, marking a year-on-year growth of 6.7%. The EBITDA for the quarter significantly improved to ₹3.8 crore from a loss of ₹5.8 crore in Q4 FY25, with the EBITDA margin expanding to 4.9% due to operational efficiencies. Consolidated Profit After Tax (PAT) for the quarter stood at ₹8.9 crore, a substantial turnaround from a loss of ₹9.7 crore in the same period last year, attributed to cost rationalization and improved business productivity.
For the full fiscal year FY26, consolidated revenue was ₹342.2 crore, compared to ₹405.5 crore in FY25. The annual EBITDA was marginally positive at ₹0.4 crore. The company highlighted ongoing strategic restructuring in its Formulation business, focusing on market positioning, product mix, and sustainable growth. Efforts to enhance field force productivity and doctor targeting contributed to operational efficiency and profitability improvements in the quarter.
The API business showed healthy traction, with discussions for new products being encouraging. The Hospital business is focused on expanding its presence in chain hospitals and nursing homes, emphasizing higher-margin products. Management is committed to improving cash flow through faster collections, receivables recovery, working capital optimization, and cost efficiencies.
Commenting on the results, Dr. Sachin Patel, Managing Director & CEO, expressed optimism about improving business momentum through operational efficiencies, productivity measures, cost optimization, and gradual recovery in core business segments. R&D investments remained consistent at around 3% of revenue, underscoring the company's commitment to developing differentiated products.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.